News & Updates
KEY POINTS TADIOS was determined to be safe and well tolerated Serum levels of IL-1RA changed significantly, a biomarker that has a correlation with severity and mortality during COVID-19 infections Improvement in fatigue observed Excerpt from the Press Release: LA JOLLA, Calif., Aug. 3, 2022 Helixmith announced topline results today from the double-blind placebo controlled…
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal injection) as a treatment of second line small cell lung cancer (SCLC).…
Ion Torrent Oncomine Myeloid MRD Assays (RUO) are the first NGS-based tests to offer simultaneous DNA and RNA analysis for myeloid MRD assessment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific today launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support…
–The NCI-backed “Molecular Targets Platform” will streamline and catalyze drug development by harmonizing data about pediatric cancer targets and pathways— Excerpt from the Press Release: PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ — Children’s Hospital of Philadelphia (CHOP) has helped launch a new computational platform that will harmonize pediatric cancer data, allowing researchers, pharmaceutical companies, and advocacy…
Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 5, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new preclinical data…
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 Excerpt from the Press Release: BASEL, Switzerland and BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today…
— Preliminary Results from the Phase 1a Trial Anticipated by Year-End — Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced initiation of a Phase 1a clinical trial of STAR-0215 in…
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM Eastern Time – Excerpt from the Press Release: NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS:…
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to adverse events (AEs) Data demonstrate the translation of sGC multi-dimensional pharmacology…
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?